Aortic stenosis
Early Surgery Provides Durable Survival Advantage in Asymptomatic Severe Aortic Stenosis: Final 10-Year Outcomes from the RECOVERY Trial
Key Points:
- Over a decade of follow-up, early surgical aortic valve replacement (AVR) continued to confer a substantial survival advantage over conservative management in asymptomatic patients with very severe aortic stenosis (AS).
- Building on the original 2020 results, early surgery reduced cardiovascular mortality by 90% and all-cause mortality by more than half, without any operative deaths—confirming the long-term durability and safety of an early-intervention strategy.
PARTNER 3 Trial: Lower Risk of Death, Stroke and Rehospitalization in Patients with Severe Aortic Stenosis and Low Surgical Risk Treated with TAVR
A randomized controlled trial led by Dr. M.J. Mack, published in the New England Journal of Medicine, showed that in patients with severe aortic stenosis and a low surgical risk, treatment with transcatheter aortic valve replacement (TAVR) with a balloon expandable valve was associated with a lower risk of stroke, death or rehospitalization by 1 year when compared to surgery.
